Observational study of patients with fibrosing interstitial lung disease in intensive care for respiratory failure
Prospective Multicenter Cohort of Patients With Fibrosing Interstitial Lung Disease Admitted to Intensive Care or Critical Care Units for Acute Respiratory Failure
This study looks at patients with fibrosing lung diseases who end up in intensive care for breathing problems to see how many survive after six months and what factors might affect their chances.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Bobigny) |
| Trial ID | NCT06855004 on ClinicalTrials.gov |
What this trial studies
This prospective, multicenter study focuses on patients with fibrosing interstitial lung diseases (ILD) who are admitted to intensive care units (ICUs) due to acute respiratory failure (ARF). The study aims to assess 6-month survival rates following ICU admission and identify prognostic factors for mortality. It also seeks to characterize ICU and hospital mortality rates, addressing the clinical challenges faced in managing these patients. The study highlights the severe complications associated with ILD and the need for evidence-based guidance in their treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of chronic interstitial lung disease requiring intensive care for acute respiratory failure.
Not a fit: Patients who are under legal guardianship, hospitalized for psychiatric reasons, pregnant, or already enrolled in the study may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into survival outcomes and management strategies for patients with fibrosing interstitial lung disease experiencing acute respiratory failure.
How similar studies have performed: While studies on acute respiratory failure in ILD exist, this specific approach focusing on a multicenter cohort and survival outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Hospitalization in intensive care for acute respiratory failure 2. Requirement for standard oxygen therapy with an O2 flow rate \> 6 l/min, high-flow oxygen therapy, or mechanical ventilation (non-invasive or invasive) 3. Age ≥ 18 years 4. Patient (male or female) with chronic interstitial lung disease (ILD) 1. Diagnosis of chronic ILD confirmed by a multidisciplinary discussion (MDD) prior to admission to intensive care, or 2. Diagnosis of chronic ILD made during the intensive care stay due to the acute episode and confirmed by an expert opinion. Exclusion Criteria: 1. Patient under legal guardianship or with restricted freedom 2. Patient hospitalized for psychiatric reasons or with a severe psychiatric illness causing a disability, subject to legal protection measures 3. Pregnant woman 4. Patient already enrolled in the study
Where this trial is running
Bobigny
- Hôpital Avicenne APHP Réanimation médico-chirurgicale — Bobigny, France (Recruiting)
Study contacts
- Study coordinator: Nathan EBSTEIN, Dr
- Email: nathan.ebstein@aphp.fr
- Phone: 01 48 95 22 80
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.